Entities / Company
Addex Therapeutics.
Swiss public company
- Reports this week
- 0
- Active events
- 0
- Connections
- 18
What's happening
Reports per dayLast 90 days
90 days agoDrag either end to show only events that began in that periodToday
Earlier this month
-
Indivior and Addex Therapeutics regained full global rights to GABAB PAM assets.Some support2 reports
-
Addex Therapeutics and Indivior are partnering on a drug candidate.Some support3 reports1 development inside
-
Addex Therapeutics and Bayer Aktiengesellschaft are being compared as healthcare companies.Some support1 report
One to three months ago
Gone quiet
No new reports in 90+ days-
Addex Therapeutics is headquartered in Geneva, Switzerland, while also maintaining a U.S. research presence.Well supported8 reports
-
MarketBeat provided analyst recommendations and compared investment factors for Addex Therapeutics and XORTX Therapeutics.Well supported3 reports
-
Indivior, Addex Therapeutics, and Johnson & Johnson completed IND-enabling studies for substance use disorders and regained rights to the mGluR2 program.Speculative1 report
-
Addex Therapeutics led a CHF 2 million investment in Stalicla and appointed its CEO to the board.Speculative2 reports
No events began in the chosen period. Widen it, or reset.
Around Addex Therapeutics this week
News at the entities that move Addex Therapeutics most-
MarketBeat Mentioned togetherMarketBeat reported the consensus stock rating for Wheeler Real Estate Investment Trust, Inc.Moves Addex Therapeutics
-
Switzerland Shared contextConflict is causing soaring fuel prices in Switzerland, leading motorists to cross borders for cheaper gas and sparking political debate.Moves Addex Therapeutics
-
Cambridge Shared contextCambridge is attracting talent and innovation, with AI and tech companies driving demand for office space.Moves Addex Therapeutics
-
Geneva Shared contextA consultative meeting on Sudan was held in Geneva, supported by Trump's adviser and the African Union.Moves Addex Therapeutics
Connections
The 6 strongest of 18, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
Indivior Operational
Indivior and Addex Therapeutics are engaged in an ongoing operational partnership focused on the development of a GABAB PAM drug candidate.
-
Mikhail Kalinichev Structural
Mikhail Kalinichev holds the role of Head of Translational Science at Addex Therapeutics.
-
MarketBeat Mentioned together
MarketBeat provides analyst ratings and market data coverage for Addex Therapeutics.
-
Switzerland Shared context
Addex Therapeutics is a biopharmaceutical company that operates and is headquartered in Switzerland.
-
Cambridge Shared context
Addex Therapeutics maintains a research presence within the geographical context of Cambridge.
-
Geneva Shared context
Addex Therapeutics is a company headquartered and operating from the city of Geneva.
History
Events by the month they beganSeptember 2026
3 eventsJune 2026
5 events- Addex Therapeutics and Indivior are partnering on a drug candidate.
- Addex Therapeutics is headquartered in Geneva, Switzerland, while also maintaining a U.S. research presence.
- MarketBeat provided analyst recommendations and compared investment factors for Addex Therapeutics and XORTX Therapeutics.
- Indivior, Addex Therapeutics, and Johnson & Johnson completed IND-enabling studies for substance use disorders and regained rights to the mGluR2 program.
- Addex Therapeutics led a CHF 2 million investment in Stalicla and appointed its CEO to the board.